Advertisement

Pharmaceutical Research

, Volume 31, Issue 2, pp 449–465 | Cite as

Use of a Fundamental Approach to Spray-Drying Formulation Design to Facilitate the Development of Multi-Component Dry Powder Aerosols for Respiratory Drug Delivery

  • Susan Hoe
  • James W. Ivey
  • Mohammed A. Boraey
  • Abouzar Shamsaddini-Shahrbabak
  • Emadeddin Javaheri
  • Sadaf Matinkhoo
  • Warren H. Finlay
  • Reinhard Vehring
Research Paper

Abstract

Purpose

A fundamental approach incorporating current theoretical models into aerosol formulation design potentially reduces experimental work for complex formulations. A D-amino acid mixture containing D-Leucine (D-Leu), D-Methionine, D-Tryptophan, and D-Tyrosine was selected as a model formulation for this approach.

Methods

Formulation design targets were set, with the aim of producing a highly dispersible D-amino acid aerosol. Particle formation theory and a spray dryer process model were applied with boundary conditions to the design targets, resulting in a priori predictions of particle morphology and necessary spray dryer process parameters. Two formulations containing 60% w/w trehalose, 30% w/w D-Leu, and 10% w/w remaining D-amino acids were manufactured.

Results

The design targets were met. The formulations had rugose and hollow particles, caused by deformation of a crystalline D-Leu shell while trehalose remained amorphous, as predicted by particle formation theory. D-Leu acts as a dispersibility enhancer, ensuring that both formulations: 1) delivered over 40% of the loaded dose into the in vitro lung region, and 2) achieved desired values of lung airway surface liquid concentrations based on lung deposition simulations.

Conclusions

Theoretical models were applied to successfully achieve complex formulations with design challenges a priori. No further iterations to the design process were required.

KEY WORDS

antimicrobial D-amino acids in silico lung particle formation model spray drying 

Notes

Acknowledgments and Disclosures

M. A. Boraey and R. Vehring would like to thank the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Alberta Innovates Technology Futures (AITF) for their financial support.

References

  1. 1.
    Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5–S23.PubMedCrossRefGoogle Scholar
  2. 2.
    Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38:728–46.CrossRefGoogle Scholar
  3. 3.
    Nandiyanto ABD, Okuyama K. Progress in developing spray-drying methods for the production of controlled morphology particles: from the nanometer to submicrometer size ranges. Adv Powder Technol. 2011;22:1–19.CrossRefGoogle Scholar
  4. 4.
    Dobry DE, Settell DM, Baumann JM, Ray RJ, Graham LJ, Beyerinck RA. A model-based methodology for spray-drying process development. J Pharm Innov. 2009;4:133–42.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Ivey JW, Vehring R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng. 2010;34:1036–40.CrossRefGoogle Scholar
  6. 6.
    Boraey MA, Matinkhoo S, Vehring R. A new time and cost effective approach for the development of microparticles for pulmonary drug delivery. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Respiratory drug delivery Europe, vol. 2. Davis Healthcare International Publishing: Berlin, Germany; 473. p. 478–2011.Google Scholar
  7. 7.
    Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409:156–63.PubMedCrossRefGoogle Scholar
  8. 8.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros. 2012;11:163–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Cava F, Lam H, de Pedro MA, Waldor MK. Emerging knowledge of regulatory roles of d-amino acids in bacteria. Cell Mol Life Sci. 2011;68:817–31.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol. 2008;6:199–210.PubMedCrossRefGoogle Scholar
  11. 11.
    Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ. Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? J Cyst Fibros. 2012;11:173–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Perez LRR, Barth AL. Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa. Braz J Infect Dis. 2011;15:301–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11:293–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Tingpej P, Elkins M, Rose B, Hu H, Moriarty C, Manos J, et al. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. Respirology. 2010;15:923–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R. D-amino acids trigger biofilm disassembly. Science. 2010;328:627–9.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Sanchez Z, Tani A, Kimbara K. Extensive reduction of cell viability and enhanced matrix production in pseudomonas aeruginosa PAO1 flow biofilms treated with a D-amino acid mixture. Appl Environ Microbiol. 2013;79:1396–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol Bioeng. 1998;59:261–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Javaheri E, Shemirani FM, Pichelin M, Katz IM, Caillibotte G, Vehring R, et al. Deposition modeling of hygroscopic saline aerosols in the human respiratory tract: comparison between air and helium-oxygen as carrier gases. J Aerosol Sci. 2013. doi: 10.1016/j.jaerosci.2013.04.010.Google Scholar
  20. 20.
    Lange CF, Hancock REW, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci. 2001;90:1647–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Hasan MA, Lange CF. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. J Aerosol Med. 2007;20:282–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv. 2007;4:297–313.PubMedCrossRefGoogle Scholar
  23. 23.
    Finlay WH, Stapleton KW, Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J Aerosol Sci. 1997;28:1301–9.CrossRefGoogle Scholar
  24. 24.
    Stahlhofen W, Rudolf G, James AC. Intercomparison of experimental regional aerosol deposition data. J Aerosol Med. 1989;2:285–308.CrossRefGoogle Scholar
  25. 25.
    Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 2012;426:100–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Son YJ, Worth Longest P, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013;443:137–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Sou T, Kaminskas LM, Nguyen T-H, Carlberg R, McIntosh MP, Morton DAV. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur J Pharm Biopharm. 2013;83:234–43.CrossRefGoogle Scholar
  28. 28.
    Hoe S, Matinkhoo S, Boraey MA, Ivey JW, Shamsaddini-Shahrbabak A, Finlay WH, et al. Substitution of L-Leucine with D-Leucine in spray-dried respirable powders for control of Pseudomonas aeruginosa infection. Chapel Hill: International Society for Aerosols in Medicine (ISAM); 2013.Google Scholar
  29. 29.
    Matinkhoo S, Hoe S, Boraey MA, Shamsaddini-Shahrbabak A, Finlay WH, and Vehring R: Spray drying D-amino acids to develop respirable dry powder for the treatment of Pseudomonas aeruginosa biofilms. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition: Chicago, IL,, 2012.Google Scholar
  30. 30.
    Adi S, Adi H, Tang P, Traini D, Chan HK, Young PM. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008;35:12–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303–16.PubMedCrossRefGoogle Scholar
  32. 32.
    Ogan Ó, Li J, Tajber L, Corrigan OI, Healy AM. Particle engineering of materials for oral inhalation by dry powder inhalers. I - Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int J Pharm. 2011;405:23–35.CrossRefGoogle Scholar
  33. 33.
    Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009–29.PubMedCrossRefGoogle Scholar
  34. 34.
    Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass-transition temperatures. Pharm Res. 1995;12:799–806.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhou DL, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci. 2002;91:1863–72.PubMedCrossRefGoogle Scholar
  36. 36.
    Dranca I, Bhattacharya S, Vyazovkin S, Suryanarayanan R. Implications of global and local mobility in amorphous sucrose and trehalose as determined by differential scanning calorimetry. Pharm Res. 2009;26:1064–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Ekdawi-Sever N, De Pablo JJ, Feick E, Von Meerwall E. Diffusion of sucrose and α, α-trehalose in aqueous solutions. J Phys Chem A. 2003;107:936–43.CrossRefGoogle Scholar
  38. 38.
    Umecky T, Kuga T, Funazukuri T. Infinite dilution binary diffusion coefficients of several α-amino acids in water over a temperature range from (293.2 To 333.2) K with the taylor dispersion technique. J Chem Eng Data. 2006;51:1705–10.CrossRefGoogle Scholar
  39. 39.
    Chan TL, Lippmann M. Experimental measurements and empirical modelling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J. 1980;41:399–409.PubMedCrossRefGoogle Scholar
  40. 40.
    Heyder J. Gravitational deposition of aerosol particles within a system of randomly oriented tubes. J Aerosol Sci. 1975;6:133–7.CrossRefGoogle Scholar
  41. 41.
    Heyder J, Gebhart J. Gravitational deposition of particles from laminar aerosol flow through inclined circular tubes. J Aerosol Sci. 1977;8:289–95.CrossRefGoogle Scholar
  42. 42.
    Ingham DB. Diffusion of aerosols from a stream flowing through a cylindrical tube. J Aerosol Sci. 1975;6:125–32.CrossRefGoogle Scholar
  43. 43.
    Vehring R. Red-excitation dispersive Raman spectroscopy is a suitable technique for solid-state analysis of respirable pharmaceutical powders. Appl Spectrosc. 2005;59:286–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Ballesteros D, Vehirng R. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder Technol. 2013;236:171–8.CrossRefGoogle Scholar
  45. 45.
    Vehring R, Ivey JW, Williams L, Joshi V, Dwivedi S, and Lechuga-Ballesteros D: High-sensitivity analysis of crystallinity in respirable powders using low-frequency shift Raman spectrocopy. In: RN Dalby, PR Byron, J Peart, JD Suman, and PM Young, editors, Respiratory drug delivery Vol II. Davis Healthcare International Publishing; 2012. pp. 641–644.Google Scholar
  46. 46.
    Shamsaddini-Sharbabak A, Vehring R. The compression behavior of respirable powders at different relative humidity measured by a compressed bulk density tester for small sample masses. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Respiratory drug delivery, vol. III. River Grove: Davis Healthcare International Publishing; 777. p. 780–2012.Google Scholar
  47. 47.
    Naini V, Byron PR, Phillips EM. Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers. Drug Dev Ind Pharm. 1998;24:895–909.PubMedCrossRefGoogle Scholar
  48. 48.
    Raula J, Thielmann F, Naderi M, Lehto VP, Kauppinen EI. Investigations on particle surface characteristics vs. dispersion behaviour of l-leucine coated carrier-free inhalable powders. Int J Pharm. 2010;385:79–85.PubMedCrossRefGoogle Scholar
  49. 49.
    Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH. On the suitability of k-epsilon turbulence modelling for aerosol deposition in the mouth and throat:a comparison with experiment. J Aerosol Sci. 2000;31:739–49.CrossRefGoogle Scholar
  50. 50.
    Chen XD, Sidhu H, Nelson M. Theoretical probing of the phenomenon of the formation of the outermost surface layer of a multi-component particle, and the surface chemical composition after the rapid removal of water in spray drying. Chem Eng Sci. 2011;66:6375–84.CrossRefGoogle Scholar
  51. 51.
    Roe KD, Labuza TP. Glass transition and crystallization of amorphous trehalose-sucrose mixtures. Int J Food Prop. 2005;8:559–74.CrossRefGoogle Scholar
  52. 52.
    Ding SP, Fan J, Green JL, Lu Q, Sanchez E, Angell CA. Vitrification of trehalose by water loss from its crystalline dihydrate. J Therm Anal. 1996;47:1391–405.CrossRefGoogle Scholar
  53. 53.
    Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – Implications for in vitro testing. J Aerosol Med. 1993;6:99–110.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Susan Hoe
    • 1
  • James W. Ivey
    • 1
  • Mohammed A. Boraey
    • 1
  • Abouzar Shamsaddini-Shahrbabak
    • 1
  • Emadeddin Javaheri
    • 1
  • Sadaf Matinkhoo
    • 1
  • Warren H. Finlay
    • 1
  • Reinhard Vehring
    • 1
  1. 1.Department of Mechanical EngineeringUniversity of AlbertaEdmontonCanada

Personalised recommendations